



Canadian  
Cancer Clinical  
Trials Network

Réseau canadien  
d'essais cliniques  
sur le cancer

Canadian Cancer Clinical Trials Network

# 3CTN Y8Q1 Performance Report

April 1, 2021 – June 30, 2021


## Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials.....	2
Patient Recruitment at All Network Sites.....	2
Portfolio Trials and Accruals by Region/Site.....	3
Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – British Columbia, Alberta, and Manitoba .....	3
Number of active recruiting 3CTN Portfolio trials – British Columbia, Alberta, and Manitoba .....	4
Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – Ontario .....	5
Number of active recruiting 3CTN Portfolio trials – Ontario .....	6
Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – Atlantic Region and Quebec .....	7
Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec .....	8
Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – Pediatric Cancer Centres .....	9
Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres .....	10
Section B: 3CTN Portfolio Metrics .....	11
Active Recruiting Portfolio Trials by Disease Site and Phase.....	11
Overview of Portfolio Applications – Process Efficiency.....	12
Trials Added to the 3CTN Portfolio in Y8 (April 1-Sept 29, 2021) .....	13

# Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

## Patient Recruitment at All Network Sites

**Objective:** To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years.



### Notes:

- 1861 patients were recruited to Portfolio trials in Quarter 1.
- Overall, ~33% of Adult Sites (14 out of 42) are on track to meet their Y8 target (75% above pre-3CTN baseline).
- \* Nova Scotia Health Authority's Y8Q1 recruitment was unreported.
- \*\* Pediatric progress to pre-3CTN baseline recruitment is shown. 10 Pediatric sites are on track to exceed their pre-3CTN baseline by end of Y8.

## Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – British Columbia, Alberta, and Manitoba

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Y7 Total	Y8			
								Q1	Total	% of Baseline	% of Target
CancerCare Manitoba	99	72	102	90	98	51	44	16	16	16%	9%
Western Manitoba Cancer Centre	1	0	0	0	1	1	0	0	0	0%	0%
<b>Manitoba Total</b>	<b>100</b>	<b>72</b>	<b>102</b>	<b>90</b>	<b>99</b>	<b>51</b>	<b>44</b>	<b>16</b>	<b>16</b>	<b>16%</b>	<b>9%</b>
BC Cancer – Vancouver	106	117	152	127	107	110	154	48	48	45%	26%
BC Cancer – Abbotsford	16	28	14	22	22	1	1	0	0	0%	0%
BC Cancer – Prince George	1	6	4	8	9	10	14	6	6	600%	343%
BC Cancer – Kelowna	38	40	30	28	38	33	36	10	10	26%	15%
BC Cancer – Victoria	26	44	69	64	69	78	40	10	10	38%	22%
<b>British Columbia Total</b>	<b>187</b>	<b>235</b>	<b>269</b>	<b>249</b>	<b>245</b>	<b>232</b>	<b>245</b>	<b>74</b>	<b>74</b>	<b>40%</b>	<b>23%</b>
Cross Cancer Institute	102	112	137	99	103	310	202	13	13	13%	7%
Tom Baker Cancer Centre	76	140	125	154	139	341	248	13	13	17%	10%
<b>Alberta Total</b>	<b>178</b>	<b>252</b>	<b>262</b>	<b>253</b>	<b>242</b>	<b>651</b>	<b>450</b>	<b>26</b>	<b>26</b>	<b>15%</b>	<b>8%</b>
<b>Western Region Total</b>	<b>465</b>	<b>559</b>	<b>633</b>	<b>592</b>	<b>586</b>	<b>934</b>	<b>739</b>	<b>116</b>	<b>116</b>	<b>25%</b>	<b>14%</b>

Number of active recruiting 3CTN Portfolio trials – British Columbia, Alberta, and Manitoba

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
CancerCare Manitoba	37	28	27	29	23	22	19	16	22	13	20	18	17	17
Western Manitoba Cancer Centre	0	0	0	1	1	1	1	1	1	1	1	1	1	1
BC Cancer – Vancouver	50	25	25	27	27	26	25	23	27	16	17	19	28	29
BC Cancer – Abbotsford	6	4	4	4	4	5	5	0	0	1	1	0	0	0
BC Cancer – Prince George	2	3	3	3	3	2	2	3	3	4	5	4	6	6
BC Cancer – Kelowna	23	9	10	6	6	5	5	5	7	4	5	5	5	8
BC Cancer – Victoria	12	5	6	5	5	8	7	6	6	7	9	7	10	11
Cross Cancer Institute	29	29	28	30	29	27	26	27	21	14	25	22	22	25
Tom Baker Cancer Centre	20	29	32	32	30	30	34	33	33	28	28	23	25	23

Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – Ontario

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Y7 Total	Y8			
								Q1	Total	% of Baseline	% of Target
London Health Sciences Centre	186	172	187	169	248	942	693	218	218	117%	67%
Grand River Regional Cancer Centre	20	13	43	32	34	19	24	3	3	15%	9%
Windsor Regional Cancer Centre	14	17	63	32	16	3	2	0	0	0%	0%
Juravinski Cancer Centre	181	231	247	454	345	217	142	71	71	39%	22%
Cambridge Memorial Hospital	11	2	5	4	5	8	9	0	0	0%	0%
St. Joseph's Healthcare Hamilton	21	30	54	74	40	20	54	20	20	95%	54%
Walker Family Cancer Centre	17	22	13	23	37	40	7	5	5	29%	17%
Sunnybrook Health Sciences Centre	141	229	398	363	651	638	387	137	137	97%	56%
Humber River Hospital	1	2	1	9	7	3	4	2	2	200%	114%
Michael Garron Hospital	2	2	1	7	2	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	384	533	473	720	543	267	106	106	27%	15%
Markham Stouffville Hospital	1	0	28	9	2	6	3	0	0	0%	0%
Mount Sinai Hospital	21	12	40	7	12	7	67	179	179	852%	487%
Northeast Cancer Centre	24	17	12	9	18	17	7	1	1	4%	2%
North York General Hospital	1	4	8	11	9	7	7	5	5	500%	286%
Royal Victoria Regional Health Centre	8	18	58	23	9	25	13	10	10	125%	71%
St. Michael's Hospital	19	0	27	2	1	3	0	0	0	0%	0%
Southlake Regional Health Centre	10	15	75	26	68	32	9	3	3	30%	17%
Thunder Bay Regional Health Sciences Centre	26	3	46	16	25	4	2	5	5	19%	11%
Trillium Health Partners - Credit Valley Hospital	27	5	51	10	12	10	2	1	1	4%	2%
William Osler Health System	1	0	29	13	0	16	2	0	0	0%	0%
The Ottawa Hospital Cancer Centre	132	238	396	500	850	804	483	88	88	67%	38%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	58	122	84	72	89	59	11	11	27%	15%
R.S. McLaughlin Durham Regional Cancer Centre	22	26	70	18	15	36	3	4	4	18%	10%
<b>Central Region Total</b>	<b>1323</b>	<b>1500</b>	<b>2507</b>	<b>2368</b>	<b>3198</b>	<b>3489</b>	<b>2246</b>	<b>869</b>	<b>869</b>	<b>66%</b>	<b>38%</b>

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
London Health Sciences Centre	79	45	46	46	40	47	52	54	57	45	47	44	41	42
Grand River Regional Cancer Centre	11	8	8	8	8	6	7	8	8	8	8	8	8	9
Windsor Regional Cancer Centre	4	4	4	5	5	4	4	4	3	4	2	2	2	2
Juravinski Cancer Centre	51	29	27	30	32	22	26	24	34	13	31	34	35	38
Cambridge Memorial Hospital	5	2	2	3	2	2	2	2	2	2	2	2	2	2
St. Joseph's Healthcare Hamilton	2	3	2	2	3	1	1	1	1	1	1	2	2	2
Walker Family Cancer Centre	10	8	7	8	7	6	6	8	7	8	7	7	7	6
Sunnybrook Health Sciences Centre	10	32	34	34	35	34	36	36	35	47	35	34	33	32
Humber River Hospital	0	3	3	2	2	2	2	3	2	3	2	1	1	1
Michael Garron Hospital	3	2	2	2	2	1	1	1	1	1	1	1	1	1
Princess Margaret Cancer Centre	91	71	74	81	86	78	88	89	80	80	81	82	65	68
Markham Stouffville Hospital	0	0	0	1	1	1	0	1	1	1	1	1	1	0
Mount Sinai Hospital	6	4	4	4	4	4	5	6	3	3	2	2	3	3
Northeast Cancer Centre	10	6	7	7	8	7	7	7	7	8	7	7	8	9
North York General Hospital	0	3	4	3	3	3	5	4	1	2	3	4	4	4
Royal Victoria Regional Health Centre	5	8	6	6	6	6	6	9	10	10	9	10	10	12
St. Michael's Hospital	4	1	1	1	2	2	2	3	2	2	2	1	1	1
Southlake Regional Health Centre	3	9	10	10	10	9	8	8	7	6	6	6	6	8
Thunder Bay Regional Health Sciences Centre	8	5	5	5	5	5	5	4	3	0	0	3	3	2
Trillium Health Partners - Credit Valley Hospital	9	3	3	3	4	4	4	3	6	0	0	1	4	6
William Osler Health System	0	1	1	2	2	1	2	2	2	1	1	1	3	2
The Ottawa Hospital Cancer Centre	56	38	37	41	51	41	36	34	15	10	27	29	35	37
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	26	25	25	26	21	33	33	22	21	21	21	20	21
R.S. McLaughlin Durham Regional Cancer Centre	13	3	4	3	3	3	3	2	2	0	2	1	1	3

Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Y7 Total	Y8			
								Q1	Total	% of Baseline	% of Target
Nova Scotia Health Authority	39	40	52	45	42	20	DNR	DNR	DNR	-	-
Eastern Regional Health Authority	15	4	12	8	15	16	5	2	2	13%	8%
<b>Atlantic Total</b>	<b>54</b>	<b>97</b>	<b>112</b>	<b>88</b>	<b>57</b>	<b>36</b>	<b>5</b>	<b>2</b>	<b>2</b>	<b>4%</b>	<b>2%</b>
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	76	161	149	71	155	90	53	53	61%	35%
CISSS de l'Outaouais	3	0	4	32	1	5	2	0	0	0%	0%
CHU de Québec – Université Laval, adults	180	25	144	236	99	309	372	126	126	70%	40%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	46	16	70	55	18	61	11	21	21	46%	26%
Centre Hospitalier de l'Université de Montréal (CHUM)	153	59	123	149	112	66	73	34	34	22%	13%
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	3	0	4	16	8	539	1603	525	525	17500%	10000%
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	60	12	51	49	23	15	6	1	1	2%	1%
<b>Quebec Total</b>	<b>532</b>	<b>192</b>	<b>588</b>	<b>709</b>	<b>332</b>	<b>1150</b>	<b>2157</b>	<b>760</b>	<b>760</b>	<b>143%</b>	<b>82%</b>
<b>Eastern Region Total</b>	<b>586</b>	<b>289</b>	<b>700</b>	<b>797</b>	<b>389</b>	<b>1186</b>	<b>2162</b>	<b>762</b>	<b>762</b>	<b>147%</b>	<b>84%</b>

DNR= Did Not Report



## Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
Nova Scotia Health Authority	14	12	16	17	17	19	14	17	16	DNR	DNR	DNR	DNR	DNR
Eastern Regional Health Authority	6	4	6	5	6	8	9	10	9	0	6	7	7	9
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	N/A	N/A	N/A	N/A	18	15	24	17	17	18	17	25	29
CISSS de l'Outaouais	1	1	1	1	2	2	2	2	2	2	1	1	2	1
CHU de Québec – Université Laval, adults	39	19	20	26	26	26	26	25	30	27	30	30	23	31
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	10	13	11	13	16	14	15	17	17	16	13	14	13	12
Centre Hospitalier de l'Université de Montréal (CHUM)	28	32	34	37	37	33	30	33	30	29	27	27	27	21
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	4	2	2	2	2	2	3	3	2	0	3	3	3	3
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	6	12	13	11	10	10	8	11	10	9	9	10	9	5

DNR= Did Not Report

Patients recruited to 3CTN Portfolio trials, FY2021/22 (Y8) – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Y7 Total	Y8		
								Q1	Total	% of Baseline
Alberta Children's Hospital	21	21	10	14	-	-	19	7	7	33%
BC Children's Hospital	34	46	41	31	-	-	30	10	10	29%
CancerCare Manitoba - Pediatrics	18	20	14	17	4	7	12	2	2	11%
Centre hospitalier universitaire de Sainte-Justine	42	26	44	40	38	38	51	19	19	45%
Children's Hospital - London Health Sciences Centre	12	15	26	9	-	-	5	1	1	8%
Children's Hospital of Eastern Ontario	20	18	35	31	-	-	14	6	6	30%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	14	7	17	22	21	29	10	10	59%
IWK Health Centre	20	20	16	40	-	-	6	3	3	15%
Janeway Children's Health and Rehabilitation Centre	4	3	4	4	0	0	5	2	2	50%
McMaster Children's Hospital - Hamilton Health Sciences Centre	14	20	19	28	-	-	16	10	10	71%
Montreal Children's Hospital	24	23	14	20	8	10	16	8	8	33%
Saskatchewan Pediatric Hematology Oncology Program	6	6	5	4	-	-	7	1	1	17%
Stollery Children's Hospital	11	10	26	33	-	-	20	7	7	64%
The Hospital for Sick Children	91	109	89	69	-	-	26	28	28	31%
<b>Pediatric Total</b>	<b>334</b>	<b>351</b>	<b>350</b>	<b>357</b>	<b>72</b>	<b>76</b>	<b>256</b>	<b>114</b>	<b>114</b>	<b>34%</b>


## Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
Alberta Children's Hospital	9	-	-	-	-	-	-	-	-	22	23	24	15	18
BC Children's Hospital	15	-	-	-	-	-	-	-	-	13	15	15	17	17
CancerCare Manitoba - Pediatrics	19	17	17	15	13	10	9	8	9	9	11	11	13	14
Centre hospitalier universitaire de Sainte-Justine	9	30	22	22	24	17	18	18	17	17	18	19	22	22
Children's Hospital - London Health Sciences Centre	5	-	-	-	-	-	-	-	-	14	14	15	18	16
Children's Hospital of Eastern Ontario	8	-	-	-	-	-	-	-	-	8	11	12	17	16
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	13	16	17	15	17	15	13	11	15	15	15	20	21
IWK Health Centre	9	-	-	-	-	-	-	-	-	19	20	22	23	20
Janeway Children's Health and Rehabilitation Centre	5	11	9	9	9	5	9	6	6	7	8	8	10	10
McMaster Children's Hospital - Hamilton Health Sciences Centre	8	-	-	-	-	-	-	-	-	12	13	14	17	17
Montreal Children's Hospital	5	25	25	20	21	12	16	16	13	16	17	15	22	22
Saskatchewan Pediatric Hematology Oncology Program	7	-	-	-	-	-	-	-	-	8	8	8	8	8
Stollery Children's Hospital	3	-	-	-	-	-	-	-	-	9	11	13	13	13
The Hospital for Sick Children	13	-	-	-	-	-	-	-	-	16	17	17	23	24

## Section B: 3CTN Portfolio Metrics

### Active Recruiting Portfolio Trials by Disease Site and Phase

**Objective:** To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



## Overview of Portfolio Applications – Process Efficiency

**Objective:** To improve Portfolio application processing time.

### Portfolio Approval Process Timeline<sup>1</sup>

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2015	90	85	16	7
2016	70	71	31	6
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020	41	41	27	0
2021	55	56	27	1

### Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed <sup>2</sup>	Average FPR Time (days) <sup>3</sup>	Median FPR Time (days) <sup>3</sup>
2015	6	3	47	39
2016	11	12	96	100
2017	4	5	79	74
2018	10	7	84	77
2019	16	17	112	86
2020	7	6	137	134
2021	8	10	128	127

<sup>1</sup> From Portfolio application receipt date to date of approval decision for period beginning Jan 13, 2015.

<sup>2</sup> Counts are based on the completed reviews in that calendar year. E.g., for an application submitted for review in 2019 but completed in 2020, the FPR will be counted for 2020.

<sup>3</sup> FPR process begins on the date the applicant agrees to initiate the FPR process and ends on the date when the final reviewer package is submitted to 3CTN (data based on completed FPRs).

**Link:** [Portfolio Applications Report](#)

## Trials Added to the 3CTN Portfolio in Y8 (April 1-Sept 29, 2021)

<b>Trial short title</b>	<b>Trial phase</b>	<b>Disease site</b>	<b>Complexity rating</b>	<b>Canadian trial status</b>	<b>Trial link</b>
(COG) ACNS1831	Phase III	Brain/CNS	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03871257">NCT03871257</a>
(COG) ACNS1833	Phase III	Brain/CNS	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04166409">NCT04166409</a>
(COG) ACNS2021	Phase II	Brain/CNS	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04684368">NCT04684368</a>
(OHRI) REaCT-CHRONO	Phase IV	Breast	Low/2	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04864405">NCT04864405</a>
(UHN) PLAN	Phase III	Breast	Low	Open, not yet recruiting	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04874038">NCT04874038</a>
(OHRI) REaCT-70 Study	Phase IV	Breast	Low	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04921137">NCT04921137</a>
(BCC) Hypoxia SLC / H17-02841	Phase I/II	Gastrointestinal	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03450018">NCT03450018</a>
(UHN) PASS-01	Phase II	Gastrointestinal	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04469556">NCT04469556</a>
(CCTG) PAC.3 / ALLIANCE A021806	Phase III	Gastrointestinal	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04340141">NCT04340141</a>
(MDACC) 2017-0905 / NCI-2018-01456	Phase II	Gastrointestinal	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03599752">NCT03599752</a>
(UHN) NAUTICAL	Pilot/Feasibility	Genito-Urinary	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04574960">NCT04574960</a>
(SRI) PLUTO-MPC	Phase I	Genito-Urinary	Standard	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04848909">NCT04848909</a>
(SHSC) AQuOS-II	Phase II	Genito-Urinary	Standard	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05023265">NCT05023265</a>
(UHN) CONTESSA - NeoCon	Phase II	Genito-Urinary	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04016389">NCT04016389</a>
(CCTG) CXC.2 / NRG-GY006	Phase III	Gynecological	Standard	Suspended/On hold	<a href="https://clinicaltrials.gov/ct2/show/study/NCT02466971">NCT02466971</a>
(SRI) Spartacus II	Phase II	Gynecological	Low	Open, not yet recruiting	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04890912">NCT04890912</a>
(BCC) BEV-DOSE	Phase II	Gynecological	Standard	Open, not yet recruiting	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04787289">NCT04787289</a>
(UHN) CAN-STAMP / OZM-110	Phase II/III	Gynecological	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04159155">NCT04159155</a>
(COG) AAML18P1	Phase I	Hematology	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03817398">NCT03817398</a>
(COG) ADVL18P1	Phase II	Hematology	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04203316">NCT04203316</a>
(PTCTC) ONC1701 EndRAD	Phase II	Hematology	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03509961">NCT03509961</a>
(HSC) 1000053716	Phase II	Hematology	Low	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03118986">NCT03118986</a>
(SHSC) 3242 / BRAWM	Phase II	Hematology	Standard	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04624906">NCT04624906</a>
(COG) ANHL1931	Phase III	Hematology	High	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04759586">NCT04759586</a>
(LHRI) OCELOT / ESR-18-14132	Phase II	Lung	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04335292">NCT04335292</a>
(BCC) SCION	Phase II	Lung	Standard	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04944173">NCT04944173</a>
(PedCITN) PED-CITN-03	Phase I	Neuroblastoma	High	Open, not yet recruiting	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04751383">NCT04751383</a>
(C17) PED-CITN-01 / 3CI Study	Phase I	Other	High	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04500548">NCT04500548</a>
(DFCI) BMS-BET / 19-040	Phase I	Other	High	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03936465">NCT03936465</a>
(UHN) PET-RPS / 19-5429	Not Applicable	Sarcoma	Low	Open to recruitment	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04224948">NCT04224948</a>
(COG) ARST2031	Phase III	Sarcoma	Standard	Project in Setup	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04994132">NCT04994132</a>